Amgen (AMGN) : Analyst Rating Update

Amgen (AMGN) : The consensus on Amgen (AMGN) based on 16 analyst recommendation on the company stock is 2.34, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 4 which endorses a Sell on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 analyst believes that the stock is a Buy, which can produce decent returns in the future. 10 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Amgen (AMGN) : The consensus price target for Amgen (AMGN) is $183.75 for the short term with a standard deviation of $10.37. The most optimist securities analyst among the 12 who monitor the stock believes that the stock can reach $195, however, the pessimist price target for the company is $157.

Amgen (NASDAQ:AMGN): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $153.44 and $152.95 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $156.82. The buying momentum continued till the end and the stock did not give up its gains. It closed at $156.05, notching a gain of 1.15% for the day. The total traded volume was 3,833,950 . The stock had closed at $154.27 on the previous day.

Also, Bernstein initiates coverage on Amgen (NASDAQ:AMGN).The analysts at the brokerage house have a current rating of Market Perform on the shares. The rating by the firm was issued on June 29, 2016. The company shares have rallied 1.29% from its 1 Year high price. On Jul 31, 2015, the shares registered one year high at $181.81 and the one year low was seen on Sep 28, 2015. The 50-Day Moving Average price is $153.11 and the 200 Day Moving Average price is recorded at $152.75.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Companys sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Companys products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.